Results 91 to 100 of about 6,506,258 (188)
CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén +11 more
wiley +1 more source
Table1_Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma.docx
Composite mantle cell lymphoma and classical Hodgkin lymphoma is very rare and the actual origin of it is still unclear. Here we reported a new case of composite mantle cell lymphoma and classical Hodgkin lymphoma and analyzed its molecular changes ...
Liqun Yang (145464) +4 more
core +1 more source
A guide to transcriptional cyclin‐dependent kinases in cancer
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin +2 more
wiley +1 more source
Anaplastic large-cell lymphoma.
The concept of anaplastic large-cell lymphoma (ALCL) has changed over the years because of a stream of new information and novel understanding regarding the cell of origin, biology, genetics, and clinical features of these neoplasms. This new information
European T. Cell Lymphoma Study Group +3 more
core +1 more source
Background The aim of this study was to validate the Mantle Cell Lymphoma International Prognostic Index in a population-based cohort and to study the relevance of its revisions.Design and Methods We analyzed data from 178 unselected patients with stage ...
Saskia A.M. van de Schans +4 more
doaj +1 more source
This is a retrospective review of intestinal tract biopsies from patients treated with various cellular immunotherapies (BCMA and CD19‐directed CAR T, teclistamab and rituximab therapies). We found distinct but overlapping histologic patterns across treatment groups, with lamina propria plasma cell depletion, crypt apoptotic bodies and active ...
Olivia J Leung +7 more
wiley +1 more source
Synergy of NVP-BEZ235 and enzastaurin in mantle cell lymphoma
Mantle cell lymphoma (MCL) is a neoplasm classified as a B-cell malignancy, that accounts for approximately 3 to 8% of Non-Hodgkin’s lymphoma (NHL) cases diagnosed annually. MCL is difficult to treat and seldom considered cured.
Monica Civallero, Maria Cosenza
doaj +1 more source
We present 12 cases of MCL with predominant extranodal disease, with MALToma‐like presentation, including immunogenetic profile and mutational landscape analysis, based on targeted NGS approach. Our data seem to confirm that this subset shows a more indolent clinical course than CN‐MCL and suggests that different genetic pathways may be involved.
Marco Lucioni +16 more
wiley +1 more source
ICSH Guidance on Bone Marrow Examination and Reporting
ABSTRACT Examination of the bone marrow (BM) remains fundamental to the diagnosis, classification, prognostication, and monitoring of hematolymphoid and other disorders affecting blood cell production. Since publication of the International Council for Standardization in Haematology (ICSH) guideline in 2008, advances in diagnostic technologies, disease
Wendy N. Erber +6 more
wiley +1 more source
Mantle cell lymphoma of the prostate
Lymphoma of the prostate, either primary or secondary, is veryrare. We report the case of an 82-year-old man with symptoms ofbladder outlet obstruction presumably due to benign prostatehyperplasia (BPH). He underwent an uneventful transurethral resectionof the prostate.
Abuhjar, Abdussalam, Ronald G, Gerridzen
openaire +3 more sources

